In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.
Hutchmed Completes Enrollment in Phase II Trial of Fanregratinib in FGFR2-Altered Cholangiocarcinoma
The firm expects to report topline data from the trial near the end of 2025 and may submit the data as part of a regulatory application in China.
After a promising feasibility study showing the potential of its natural language processing models, MSK has ambitions to use them in patient care.
Researchers will use the funds to identify molecular signatures linked to different disease subtypes and test drugs on brain organoids.
PCRX-201 became part of Pacira's portfolio in 2021, but was originally developed at Baylor and then by GQ Bio Therapeutics, ...
Ataraxis AI will use the new funding to bring to market its first offering, Ataraxis Breast, an AI-native prognostic/predictive platform for breast cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results